Company news

Algorae Pharmaceuticals Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

AGM Chairman Address to Shareholders

November 4, 2026

Corporate Presentation

October 29, 2026

Quarterly Activities Report and Appendix 4C Cash Flow Report

October 29, 2026

Quarterly Activities Report and Appendix 4C Cash Flow Report

October 29, 2026

Updated Securities Trading Policy

October 28, 2026

Algorae executes Licence & Supply Agreement with Umedica

October 18, 2026

Algorae executes Licence & Supply Agreement with Umedica

October 18, 2026

Peter Mac partners with Algorae on 3rd AI validation program

October 15, 2026

Notice of Annual General Meeting/Proxy Form

October 7, 2026

Change of Director's Interest Notice - DH

September 30, 2026

Date of AGM and Closing Date for Director Nominations

September 9, 2026

Notification of cessation of securities - 1AI

September 2, 2026

Appendix 4E and 2026 Annual Report

August 31, 2026

Appendix 4G and Corporate Governance Statement

August 31, 2026

Quarterly Activities Report/Appendix 4C Cashflow Statement

July 30, 2026

Peter Mac Testing Validates AlgoraeOS v2

July 2, 2026

Updated - NSW Health Public Hospital Supply Contract

July 1, 2026

Algorae Awarded NSW Health Public Hospital Supply Contract

June 30, 2026

Algorae Expands AI Drug Combination Pipeline

May 17, 2026

1AI Executes License & Supply Agreement with Torrent Pharma

May 5, 2026

Algorae and Zydus Enter Exclusive Commercial Agreement

April 27, 2026

Algorae Pharmaceuticals Ltd Raises $3.9m

April 2, 2026

TGA Accepts Initial Registration Dossier for Evaluation

April 1, 2026

Peter Mac Partners with Algorae on AI Validation

March 29, 2026

Half Year Report and Appendix 4D

February 27, 2026

Algorae Signs License and Supply Agreement with Cadila

February 8, 2026

Quarterly Activities Report /Appendix 4C Cash Flow Statement

January 27, 2026

$3 million Debt Facility Secured with ScotPac

January 20, 2026

AlgoraeOS v2 Identifies 90 Drug Combination Candidates

December 11, 2025

Algorae Receives $384,466.78 R&D Tax Incentive Refund

December 9, 2025

Peter Mac Testing Validates AlgoraeOS - v2 Launched

December 4, 2025

Algorae Signs Distribution Agreement with Dr. Reddy's

November 26, 2025

Loyalty Options Offer

November 16, 2025

Prospectus - Loyalty Options Offer

November 16, 2025

AlgoraeOS Version 2 AI Platform Launched

November 9, 2025

Algorae Signs Binding Term Sheet with Cadila Pharmaceuticals

October 19, 2025

Algorae Signs Exclusive License Agreement with Sakar

September 22, 2025

Annual Report and Appendix 4E

August 28, 2025

Algorae Receives A$318,771 R&D Cash Rebate from ATO

June 5, 2025

Peter Mac Partners with Algorae on AI Drug Targets

May 7, 2025

Algorae Receives A$451,359 R&D Cash Rebate from ATO

March 30, 2025

Half Yearly Report Announcement and Appendix 4D

February 26, 2025

Significant Cardioprotection Qualities in AI-168 Studies

November 28, 2024

24 New AI-Generated Drug Targets

November 20, 2024

AlgoraeOS Artificial Intelligence Platform Launched

September 23, 2024

Positive results from AI-116 in vitro studies

July 30, 2024

Artificial Intelligence Platform Update

March 7, 2024

Response to ASX Price Query

February 20, 2024

NTCELL Project Update

February 14, 2024

Quarterly Activities Report/Appendix 4C Cash Flow Statement

January 29, 2024

Older news releases →

Decks